China NT Pharma Group Company Limited (NT Pharma) disclosed its Monthly Return for March 2026, highlighting a sizeable equity expansion driven by a consideration issue.

Key developments

1. Issued-share increase • NT Pharma issued 274.75 million new ordinary shares on 25 March 2026 at HK$0.45 per share following shareholder approval on 15 January 2026. • The move lifted total issued shares (excluding treasury shares) to 948.99 million from 674.25 million—a 40.7% month-on-month increase.

2. Capital structure unchanged at the top level • Authorised share capital remained at 62.59 billion ordinary shares and 32.50 million preference shares, together representing US$50,100 in nominal capital. • No treasury shares were held at month-end.

3. Public-float compliance • The company confirmed compliance with the Main Board’s minimum 25% public-float requirement as of 31 March 2026.

4. Implied transaction value • At the stated issue price, the consideration shares represent approximately HK$123.64 million.

Implications

The substantial increase in issued shares enhances NT Pharma’s capital base while maintaining regulatory public-float thresholds. The unchanged authorised capital provides additional headroom for future fundraising or corporate actions without immediate need for shareholder approval.